Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Healthcare Biotechnology
Defence Therapeutics Inc. is a Canada-based biotechnology company working on engineering vaccines and antibody drug conjugates (ADC) products using its proprietary platform. The Company is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and... see more

Recent & Breaking News (CSE:DTC)

Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth

Newsfile 2 days ago

Defence Therapeutics Announces Warrant Terms Amendment

Newsfile April 5, 2024

Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Newsfile March 26, 2024

Defence Completes 2nd Tranche of Financing

Newsfile March 22, 2024

Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology

Newsfile March 4, 2024

Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update

Newsfile February 29, 2024

Defence Therapeutics Completes 1st Tranche of Financing

Newsfile January 30, 2024

Defence Financing

Newsfile January 19, 2024

Defence Begins Trading on the OTCQB and Arranges Financing

Newsfile January 12, 2024

Defence's AccuTOX(R) Impairs Lung Cancer Growth

Newsfile January 10, 2024

RETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)

Newsfile December 12, 2023

Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)

Newsfile December 11, 2023

Defence's Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors

Newsfile November 14, 2023

Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology

Newsfile November 7, 2023

Defence's AccuTOX(R) And Antigen Cross-Presentation: Discovery Leads Towards the Development of a Groundbreaking Platform

Newsfile October 25, 2023

Defence's Novel Accutox(TM) Continues to Surprise on Results Against Cancer

Newsfile October 18, 2023

Defence's Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma

Newsfile October 17, 2023

Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science

Newsfile October 10, 2023

Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, Switzerland

Newsfile October 6, 2023

Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines

Newsfile September 25, 2023